1	The Balancing Role of Distribution Speed against Varying Efficacy Levels of COVID-19
2	Vaccines under Variants
3	
4	Daniel Kim
5	H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of
6	Technology, Atlanta, GA 30332, email: <u>dkim608@gatech.edu</u>
7	
8	Pınar Keskinocak, Ph.D.
9	H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of
10	Technology, Atlanta, GA 30332, email: <u>pinar@isye.gatech.edu</u>
11	
12	Pelin Pekgün, Ph.D.
13	Moore School of Business, University of South Carolina, Columbia, SC 29208,
14	email: <u>pelin.pekgun@moore.sc.edu</u>
15	
16	Inci Yildirim, M.D., Ph.D.
17	Department of Pediatrics, Section of Infectious Diseases and Global Health, Yale School of
18	Medicine and Yale Institute of Global Health, 1 Church Street, New Haven, CT 06510,
19	email: <u>inci.yildirim@yale.edu</u>
20	
21 22	Corresponding Author: Pınar Keskinocak, Ph.D.
23	H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of
24 25	email: pinar@isye.gatech.edu, phone: +1-404-894-2325
• •	

28 ABSTRACT

29

- 30 Mutations in SARS-CoV-2 raised concerns about diminishing vaccine effectiveness against
- 31 COVID-19 caused by particular variants. Even with high initial efficacy, if a vaccine's efficacy
- 32 drops significantly against variants, or if it cannot be distributed quickly, it is uncertain whether
- the vaccine can provide better health outcomes than other vaccines. Hence, we evaluated the
- 34 trade-offs between the *speed of distribution* vs. *efficacy against infection* of multiple vaccines
- 35 when variants emerge by utilizing a Susceptible-Infected-Recovered-Deceased (SIR-D) model
- 36 and assessing the level of *infection attack rate* (IAR). Our results show that speed is a key factor
- to a successful immunization strategy to control the COVID-19 pandemic even when the
- 38 emerging variants may reduce the efficacy of a vaccine. Due to supply-chain challenges, the
- 39 accessibility and distribution of the vaccines have been hindered in many regions, especially in
- 40 low-income countries, while the second or third wave of the pandemic has occurred due to the
- 41 variants. Understanding the tradeoffs between speed and efficacy and distributing vaccines that
- 42 are available as quickly as possible are crucial to eradicate the pandemic before new variants
- 43 spread.
- 44
- 45 **KEYWORDS:** vaccination; disease modeling; COVID-19; vaccine efficacy; distribution speed

47 INTRODUCTION

Since the initial reports of a cluster of pneumonia cases of unidentified origin in Wuhan, 48 China, in December 2019, more than 265 million people around the world have been infected 49 with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).¹ Despite the 50 51 development of effective vaccines in unprecedented speed, concerns have been raised on the 52 potential reduction in efficacy of these vaccines against the new SARS-CoV-2 variants due to possible evasion from antibody recognition.^{2,3} In order to reach herd immunity, effective 53 implementation of a vaccine with sufficient efficacy against the circulating dominant variants is 54 essential. Subsequently, it becomes a trivial decision for policymakers and governments to favor 55 a vaccine with high efficacy for distribution. However, if the vaccine cannot be dispensed 56 57 quickly and/or if its efficacy drops significantly against the emerging variants compared to other 58 vaccines, the question of which vaccine should be favored is no longer trivial. Hence, the goal of 59 this study was to understand the tradeoffs between the speed of distribution vs. the change in the efficacy levels of vaccines against infection before and after the emergence of variants, which we 60 61 referred to as "initial efficacy" and "final efficacy", respectively, hereafter. 62 The slow speed of procurement and dissemination of the SARS-CoV-2 vaccines has been a 63 continual challenge, particularly for low-income countries. Many low-income countries could 64 not even procure the small amount of vaccines since the high-income countries had reserved

65 large amounts.⁴ In addition, the vaccines, especially those with high efficacies, may encounter a 66 number of administrative and supply-chain related challenges in the low-income countries. For 67 instance, the mRNA vaccines for COVID-19 require ultra-cold storage and logistics, which are 68 often not readily available or easy to acquire.^{5,6} Due to such challenges, as of December 2021,

only 8% of people in low-income countries have received at least one dose of the vaccines, in
contrast to 65% of people in high-income countries.^{7,8}

71 The distributional challenges and delays lead to continuous infections, providing an 72 opportunity to the variants of the virus to emerge, which has raised concerns regarding reduced efficacy of vaccines against emerging variants.⁹ As of December 2021, five concerning SARS-73 CoV-2 variants have been identified: B.1.1.7, B.1.351, P.1, B.1.617.2, and B.1.1.529.¹⁰ These 74 75 have been classified as the variants of concern (VOC) because they have quickly become the globally dominant forms.¹¹⁻¹⁴ The variant B.1.617.2 (delta), for instance, was classified as the 76 variant of concern by the World Health Organization (WHO) on May 11th, 2021 and quickly 77 became dominant in the United States in July 2021.^{10,15} These variants became more alarming as 78 79 multiple studies showed that the effectiveness of various vaccines decreased against the variants.¹⁶⁻¹⁹ 80

81 In this paper, we studied the trade-offs between vaccines' efficacy levels, which were subject 82 to reduction due to emerging variants and speed of vaccine distribution. We developed an 83 extended Susceptible-Infected-Recovered-Deceased (SIR-D) simulation model and assessed the infection attack rate (IAR) under different times that the virus variants emerge. A number of 84 85 studies used the extended SIR-D model with different complications to study the impact of public health interventions, including social distancing and vaccination.²⁰⁻²⁴ While some papers 86 examined the trade-offs between vaccine efficacy and distribution speed like ours.^{23,24}, to the 87 88 best of our knowledge, this is the first paper to consider the impact of a change in vaccine 89 efficacy due to the emergence of variants. Throughout this paper, we referred to vaccine 90 distribution as the entire distribution process of a vaccine including delivery to the dispensation 91 sites and administration to the population. The results of this study were aimed to guide decision92 makers in vaccine ordering during a pandemic when there are multiple types of vaccines, facing93 reduced efficacies as variants emerge.

94

95 METHODS

96 Vaccine Capacity

97 To compare different vaccine types, we categorized the level of the vaccine efficacy into

98 three ranges: "H" (High) if 90% or above, M (Moderate) if higher than 70% and lower than 90%,

99 and L (Low) if lower than 70%. We assumed that the final efficacy was always lower than the

initial efficacy. In our main simulation, we considered three initial efficacy levels ($H_i = 95\%$,

101 $M_i = 75\%$, and $L_i = 65\%$) and three final efficacy levels ($H_f = 90\%$, $M_f = 70\%$, and $L_f = 60\%$).

102 Consequently, we obtained six types of vaccines, defined by a particular initial and final efficacy,

as summarized in Table 1. These modeling choices were motivated by recent studies on vaccine

104 efficacy against variants.²⁵⁻²⁷

- 105
- 106

racie it taceffic Efficac	Table	1:	Vaccine	Efficacy	1
---------------------------	-------	----	---------	----------	---

Vaccine Type	Initial Efficacy	Final Efficacy
$H_i H_f$	95%	90%
$H_i M_f$	95%	70%
$H_i L_f$	95%	60%
$M_i M_f$	75%	70%
$M_i L_f$	75%	60%
$L_i L_f$	65%	60%

107

108 We assumed in our simulations that all vaccines required a single dose and an individual who 109 received an *effective* vaccine became fully protected against the disease upon vaccination. In 110 each simulation, only a single type of vaccine was administered, and the daily vaccine 111 distribution capacity was kept constant at $\lambda \cdot K$, where *K* represents base capacity and λ is a

multiplier. We fixed the base capacity, *K*, at 500,000, motivated from the average number of vaccine recipients in each day in the United States from December 14, 2020 to March 2, 2021, and we set a range of 1.0 to 3.0 with increments of 0.2 for the capacity multiplier λ to represent

the speed of distribution in our simulations.²⁸

116 Compartmental Epidemiological Model

117 In our study, we utilized an extended SIR-D (Susceptible-Infectious-Recovered-Deceased)

118 compartmental model, which is a simplified mathematical model of infectious diseases. In this

119 model, individuals are moving among compartments, and transitions between compartments are

120 governed by ordinary differential equations given epidemiological and vaccine parameters. We

121 implemented seven compartments: Susceptible (S), Vaccinated with immunity (V), Vaccinated-

122 susceptible (S^{ν}) , Symptomatic-infected (I_S) , Asymptomatic-infected (I_A) , Recovered (R), and

123 Deceased (D). When Susceptible population received vaccines, they entered either the

124 Vaccinated with immunity (V) compartment if the vaccine was effective, or the Vaccinated-

125 susceptible (S^{ν}) compartment, otherwise. Both Susceptible and Vaccinated-susceptible

126 populations transitioned to either the Symptomatic-infected (I_S) or Asymptomatic-infected (I_A)

127 compartment, once they made infectious contacts with the infected population. Symptomatic-

128 infectious population then moved to either the *Recovered* (*R*) or *Deceased* (*D*) compartment. We

assumed that asymptomatic patients always recovered in our model. The transition diagram of

the extended SIR-D model is depicted in Figure 1.



131

Figure 1: Transition diagram of the extended SIR-D model, in which each move is dependent on
the epidemiological and vaccine parameters; symptomatic and asymptomatic
transmission rates, respectively; : symptomatic and asymptomatic recovery rates,
respectively; : decease rate of a symptomatic patient; : efficacy of the vaccine; : ratio of the
daily vaccine capacity to the size of the unvaccinated susceptible population (i.e.,

138

139 We chose the epidemiological parameter values that govern the transitions in the 140 compartment model based on the estimated SARS-CoV-2 characteristics in various studies. The 141 infectious periods of a symptomatic patient and an asymptomatic patient were studied to be 14 days and 8 days, respectively.^{29,30} Therefore, we set the recovery rates of symptomatic patients 142 143 () and asymptomatic patients () at 1/14 and 1/8, respectively. In addition, the CDC has 144 developed COVID-19 Pandemic Planning Scenarios and provided parameter values to use in a mathematical model.³¹ Accordingly, we assumed that 60% of the susceptible population who 145 146 made infectious contacts became symptomatic. In addition, we used 2.3 for the reproduction 147 number (), which is often employed by epidemiologists to represent the infectivity of a disease. The symptomatic infection fatality rate (IFR-S) of COVID-19, the proportion of deaths among 148 symptomatic infected individuals, was estimated as 1.3%.³² Given the reproduction number of 149

150 2.3 and the IFR-S, we set the symptomatic-transmission rate (β_s) to be 0.22031 and the death rate (μ) to be 0.0032. We assumed that the asymptomatic-transmission rate (β_a) was 75% of the 151 symptomatic-transmission rate.³³ We used R-software to run the simulations with a population 152 153 size (N) of 330 million (approximate population of the United States). Since our main goal was 154 to analyze the trade-offs between distribution speed and vaccine's efficacy under variants, we 155 started the simulation only after when the vaccine became available and initialized it such that 156 around 28% of the population had already been infected. Thus, we set 2.90% of the population as 157 symptomatic-infected, 1.15% as asymptomatic-infected, 24.44% as recovered, and 0.14% as 158 deceased. These estimates were motivated by the *confirmed* cumulative cases and deaths as of December 14, 2020, the first day of vaccine distribution in the United States.³⁴ However, we 159 160 multiplied the number of *confirmed* infections by six and increased the number of *confirmed* deaths by 35% in line with the findings of Wu et al. (2020) and Noh and Danuser (2021), who 161 reported that the number of COVID-19 confirmed cumulative cases was underestimated, and 162 Kung et al. (2020), who showed the same for confirmed deaths.³⁵⁻³⁷ The initial values in other 163 compartments were estimated using the epidemiological parameters defined previously. All 164 165 parameters used in the extended SIR-D model are summarized in Table 2 and the non-linear 166 system of ordinary differential equations (ODEs) is as follows:

$$\frac{dS}{dt} = -\left(\min\left(1, \frac{\lambda \cdot K}{S \cdot N}\right) + \beta_S\left(1 - \min\left(1, \frac{\lambda \cdot K}{S \cdot N}\right)\right)I_S + \beta_A\left(1 - \min\left(1, \frac{\lambda \cdot K}{S \cdot N}\right)\right)I_A\right)S$$
$$\frac{dV}{dt} = e \cdot \min\left(1, \frac{\lambda \cdot K}{S \cdot N}\right) \cdot S$$
$$\frac{dS^v}{dt} = (1 - e) \cdot \min\left(1, \frac{\lambda \cdot K}{S \cdot N}\right) \cdot S - (\beta_S I_S + \beta_A I_A) \cdot S^v$$
$$\frac{dI_S}{dt} = p_S \cdot \left[\beta_S\left(1 - \min\left(1, \frac{\lambda \cdot K}{S \cdot N}\right)\right)I_S + \beta_A\left(1 - \min\left(1, \frac{\lambda \cdot K}{S \cdot N}\right)\right)I_A\right] \cdot S$$

$$+ p_{S} \cdot (\beta_{S}I_{S} + \beta_{A}I_{A}) \cdot S^{v} - \gamma_{S}I_{S} - \mu_{S}I_{S}$$

$$\frac{dI_{A}}{dt} = (1 - p_{S}) \cdot \left[\beta_{S}\left(1 - \min\left(1, \frac{\lambda \cdot K}{S \cdot N}\right)\right)I_{S} + \beta_{A}\left(1 - \min\left(1, \frac{\lambda \cdot K}{S \cdot N}\right)\right)I_{A}\right] \cdot S$$

$$+ (1 - p_{S}) \cdot (\beta_{S}I_{S} + \beta_{A}I_{A}) \cdot S^{v} - \gamma_{A}I_{A}$$

$$\frac{dR}{dt} = \gamma_{S}I_{S} + \gamma_{A}I_{A}$$

$$\frac{dD}{dt} = \mu_S I_S$$

Parameter	Description	Value									
β_s, β_a	Transmission rate	0.22031, 0.16523									
γ_s, γ_a	Recovery rate	1/14, 1/8									
μ_S	Death rate	0.0032									
Ν	Population size	330 million									
p_{S}	Probability of developing symptoms	0.6									
е	Vaccine efficacy	See Table 1									
K	Base capacity	500,000									
λ	Capacity multiplier	1.0 to 3.0 with increments of 0.2									
	Table 2: Parameters used in the extended SIR-D Model										

167

168

We ran the simulation on a one-year planning horizon under different *mutation times* (i.e., the time at which the emerging variants becomes dominant and cause a decrease in a vaccine's efficacy) within the range of day 5 to day 40 with a discrete step size of 5 days, and different *capacity multipliers* (λ) within the range of 1.0 to 3.0 with a discrete step size of 0.2 to capture the vaccine distribution speed. We evaluated the impact of each vaccine type using IAR as the main health outcome.

We first ran our simulation without the presence of any vaccines, which gave an estimated

176 **RESULTS**

177

IAR of approximately 81% and IFR-S of 2%. The daily infection peak (i.e., the highest 178 179 percentage of the population who get newly infected on a single day) occurred on day 24, at 180 which 1% of the population got newly infected. Table 3 shows the estimated IAR under different capacity multipliers (λ) when the mutation 181 times are day 5 and day 25. We report the full results with different mutation times in 182 183 Supplemental Materials. When the mutation time is day 5, the level of IAR is between 60% and 184 65% when the capacity multiplier is 3.0 (1.5M doses/day) and between 72% and 75% when the 185 capacity multiplier is 1.0 (0.5M doses/day), depending on the selected vaccine type. When the 186 mutation time is day 25, the level of IAR is smaller compared to when the mutation time is day 5, 187 and the decrease in IAR due to the increase in capacity multiplier is larger.

188

Capacity		Mu	tation T	ime = Da	ay 5		Mutation Time = Day 25						
Multiplier (λ)	$H_i H_f$	$H_i M_f$	$H_i L_f$	$M_i M_f$	$M_i L_f$	$L_i L_f$	-	$H_i H_f$	$H_i M_f$	$H_i L_f$	$M_i M_f$	$M_i L_f$	$L_i L_f$
3.0	60.19	63.02	64.63	63.55	65.17	65.45		59.81	60.98	61.64	63.13	63.86	65.01
2.8	61.16	63.92	65.48	64.43	65.99	66.25		60.80	61.96	62.63	64.02	64.74	65.83
2.6	62.18	64.86	66.36	65.34	66.84	67.09		61.84	63.00	63.65	64.95	65.66	66.69
2.4	63.25	65.84	67.27	66.28	67.72	67.95		62.92	64.07	64.72	65.92	66.61	67.58
2.2	64.38	66.86	68.22	67.27	68.64	68.85		64.06	65.20	65.83	66.93	67.60	68.50
2.0	65.55	67.91	69.20	68.29	69.58	69.78		65.26	66.37	66.98	67.98	68.62	69.45
1.8	66.79	69.01	70.22	69.36	70.56	70.74		66.52	67.59	68.18	69.07	69.68	70.44
1.6	68.08	70.16	71.27	70.47	71.58	71.74		67.83	68.86	69.42	70.20	70.78	71.47
1.4	69.44	71.35	72.36	71.62	72.63	72.77		69.22	70.19	70.71	71.38	71.92	72.53
1.2	70.87	72.58	73.48	72.82	73.72	73.84		70.67	71.57	72.05	72.61	73.10	73.63
1.0	72.37	73.86	74.65	74.06	74.85	74.95		72.20	73.00	73.43	73.89	74.32	74.77

189 190 Table 3: Infection attack rate (%) under different capacity multipliers and vaccine types whenmutation time is day 5 and day 25

192	Figure 2 and Figure 3 present the contour plot and the two-dimensional plot of the IAR in
193	Table 3, respectively. Figure 2 shows that even vaccine- $L_i L_f$ can achieve a lower IAR than
194	vaccine- H_iH_f if the capacity multiplier of vaccine- L_iL_f is high compared to that of vaccine- H_iH_f .
195	For instance, when the capacity multiplier of vaccine- H_iH_f is 1.0 and the mutation time is day 5,
196	72.3% of the population is infected. However, if the capacity multiplier of vaccine- $L_i L_f$ is 1.48
197	(or higher), 72.2% (or less) of the population is infected. We present the minimum required
198	capacity multiplier of all vaccine types to achieve a lower IAR than vaccine- H_iH_f with the
199	capacity multiplier of 1.0 and 1.6 under different mutation times in Supplemental Materials.
200	Figure 4 compares the daily new infections from day 5 to day 50 with vaccine- $H_i L_f$ vs.
201	vaccine- $M_i M_f$. In this figure, the mutation time is early (on day 5) and comes before the daily
202	infection peak, and thus, vaccine- $M_i M_f$ results in a better IAR than vaccine- $H_i L_f$ for all capacity
203	multipliers. Specifically, after the peak of daily new infections is reached for each vaccine, the
204	number of daily infections drops at a faster rate when vaccine- $M_i M_f$ is administered. On the
205	other hand, when the mutation time comes after the daily infection peak (not shown in the figure),
206	vaccine- $H_i L_f$ achieves a lower IAR than vaccine- $M_i M_f$ for all capacity multipliers.
207	







Figure 2: Graphical representation of infection attack rate under different capacity multipliers

211

with different vaccine types when mutation time is (a) day 5 and (b) day 25



Figure 3: Two-dimensional plot of infection attack rate under different capacity multipliers with different vaccine types when mutation time is (a) day 5 and (b) day 25

215

212



217 218

Figure 4: Daily new infections from day 5 to day 50 with vaccine- and vaccine- when
the capacity multiplier (is 3 and the mutation time is day 5

221

222 DISCUSSION

In this study, we utilized an extended SIR-D model to simulate the trajectory of an infectious disease under the intervention of different kinds of vaccines of which efficacies decrease against the variants of the disease and different mutation times. We have demonstrated that the speed of the vaccine distribution is a key factor to achieve low IAR levels, even though the vaccine may have high efficacy both before and after the variants emerge.

228 Our study showed that a vaccine with low initial and final efficacy levels (vaccine-)

could achieve a lower IAR than a vaccine with high initial and final efficacy levels (vaccine-

-) if the former can be distributed more quickly than the latter, regardless of the mutation
- time. In our simulation, when the mutation time was day 25 and the capacity multiplier of
- vaccine- was 1.0 (0.5M doses/day), 72.2% of the population got infected. If the capacity

233	multiplier of vaccine- $L_i L_f$ was 1.47 (0.73M doses/day or higher), 72.1% (or less) of the
234	population was infected (Table 3). Even for vaccines with the same initial efficacy, such as
235	vaccine- H_iH_f and vaccine- H_iL_f , this result remained robust—vaccine- H_iL_f with a capacity
236	multiplier of 1.18 (0.59M doses/day) or higher achieved a lower IAR than vaccine- $H_i H_f$ with a
237	capacity multiplier of 1.0 (0.5M doses/day). Since the start of the COVID-19 vaccination process,
238	the speed of the vaccine distribution has been slow due to numerous reasons, including limited
239	and uncertain vaccine supply and various logistics and storage challenges. Despite the continuing
240	effort of increasing production capacities, vaccine manufacturers, especially those who produce
241	mRNA vaccines with new technology, have been struggling to secure sufficient supply of
242	vaccine ingredients, storage containers, and more, due to the demand from billions of people
243	around the world. ³⁸ In addition, mRNA vaccines need to be stored in ultra-cold freezers under
244	specific expiration dates, although many communities, especially in the low-income countries,
245	lack or cannot afford such infrastructure, leading to a limited number of administration sites.
246	Besides the mRNA vaccines, numerous vaccines that require the same level of the resources that
247	the seasonal flu vaccine consumes have been developed and administered throughout the world.
248	These vaccines may prevent vaccine wastage, enable efficient production and distribution using
249	the existing vaccine supply chain, and facilitate a faster rate of vaccination. ³⁹ Hence, despite
250	having lower efficacy than mRNA vaccines, those vaccines that have the potential for faster
251	distribution may be more beneficial.
252	Increasing the doses distributed per day, i.e., the capacity multiplier (λ), of any vaccine type
253	is always beneficial as it reduces the size of the susceptible population and can, eventually,

achieve herd immunity. Our study showed that the level of IAR always decreased when the

255 capacity multiplier was higher, with the largest impact observed for vaccine- H_iH_f . In particular,

256 when we compared the impact of changing the capacity multiplier from 1.0 to 3.0 for vaccine-257 H_iH_f , vaccine- M_iM_f , and vaccine- L_iL_f , IAR changed from 72.20% to 59.81% for H_iH_f , from 73.89% to 63.13% for $M_i M_f$, and from 74.77% to 65.01% for $L_i L_f$, when the difference between 258 259 the initial and final efficacy was 5% for all the vaccine types and the mutation time was day 25. 260 In addition, if vaccine- H_iH_f could be distributed at a faster rate, the minimum required capacity multiplier (λ) of vaccine- $L_i L_f$ to achieve a lower IAR than vaccine- $H_i H_f$ was even larger. For 261 example, when the mutation time was day 25, the capacity multiplier of vaccine- $L_i L_f$ needed to 262 263 be at least 1.47 to achieve a lower IAR than vaccine- H_iH_f with the capacity multiplier of 1.0. On 264 the other hand, when the vaccine- H_iH_f 's capacity multiplier was 1.6, the capacity multiplier of vaccine- $L_i L_f$ needed to be at least 2.35. Thus, even though the difference in the capacity 265 multiplier of vaccine- H_iH_f was only 0.60, that of vaccine- L_iL_f was 0.88. However, increasing 266 the capacity multiplier, i.e., the speed of distribution, for vaccine- H_iH_f , which represents mRNA 267 vaccines in our model, may be much more challenging than that for vaccine- $L_i L_f$, as described 268 269 above, including economic burden, complications in vaccination programs, and unsophisticated 270 infrastructure. In such cases, it may be more beneficial to allocate resources towards distributing 271 a lower efficacy vaccine at a faster rate as our study shows.

Forecasting the time when the peak infections occur and when the variants emerge is also critical to choosing which type of vaccine to distribute for maximizing public health benefits. If the mutation time comes after the daily infection peak, a vaccine with a higher initial efficacy always achieves a lower IAR than a vaccine with lower initial efficacy. However, if the mutation time comes before the daily infection peak, the final efficacy level determines which vaccine type achieves a lower IAR under the same capacity multiplier. For example, when we compared vaccine- H_iH_f and vaccine- M_iM_f with a capacity multiplier of 1.0 for each, the daily infection

279 peak occurred on day 22 for both vaccines. Then, the administration of vaccine- M_iM_f , which has an initial efficacy of 75% and final efficacy of 70%, resulted in an IAR of 74.06%, whereas the 280 administration of vaccine- H_iL_f , which has an initial efficacy of 95% and final efficacy of 60%, 281 282 resulted in an IAR of 74.65% (Figure 4). This is because an effective vaccination program 283 achieves the highest reduction in the number of new infections *before* the daily infection peak. 284 Afterwards, even with a higher initial efficacy, a vaccine with a lower final efficacy cannot 285 reduce the size of the susceptible population as much as a vaccine with a lower initial efficacy 286 and a higher final efficacy. Active genomic surveillance that studies the evolvement of the virus 287 is critical to identify a new variant and study its influence on the spread of the disease and the vaccine efficacy.⁴⁰ However the genomic surveillance has not received as much attention and the 288 coverage is still low.^{41,42} Our results demonstrated that an expedited detection of the variants and 289 290 their impact is vital to the choice of a vaccine to minimizes the IAR.

291 Limitation

292 We acknowledge some limitations of this study. Our compartmental model provided insights 293 on the trade-offs between speed and efficacy against emerging variants without incorporating the 294 impact of other interventions. However, it can be extended to capture more realistic trajectory of SARS-CoV-2, including more compartments or time-dependent epidemiological parameters.^{43,44} 295 296 In addition, we assumed that the population gains immunity as soon as they receive effective 297 vaccines and that every type of vaccine requires a single dose. In practice, the majority of the 298 authorized vaccines require two doses with three to four weeks apart application and it may take 299 several days to gain immunity after vaccination. Moreover, we did not consider any type of non-300 pharmaceutical interventions. Depending on the number of people who conform to the

interventions, such as social distancing and mask mandates, the probability of infectious contactsmay vary over time.

303

304 CONCLUSION

305 Overall, our results suggested that the administration of a vaccine with high efficacy against 306 both the original strain and the variants may not always lead to a low number of cumulative 307 infections if it cannot be distributed as quickly as other vaccine types with lower efficacies. 308 Despite the vast efforts for worldwide vaccination, the vaccine distribution has been an ongoing 309 challenge due to production shortages, economic constraints, and the lack of advanced supply-310 chain infrastructure, which is critical to distribute some of the high-efficacy vaccines. Due to 311 these challenges, the accessibility and distribution of the vaccines have been hindered especially in many low- and middle-income countries.⁴⁵⁻⁴⁷ It is critical to distribute available vaccines as 312 313 quickly as possible and vaccinate more people to reach herd immunity before new variants 314 spread. Our study demonstrated that a vaccine with a relatively lower efficacy can achieve at 315 least as good health outcomes as their higher efficacy counterparts, as long as it can be 316 distributed more quickly. We hope that our study provides guidance to decision makers on the 317 tradeoffs between speed and efficacy, highlighting the critical role of speed of vaccination during 318 a pandemic as variants that decrease efficacy of vaccines emerge.

319

320 **REFERENCES**

World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard,
 (2020).

- 3232Karim, S. S. A. & Karim, Q. A. Omicron SARS-CoV-2 variant: a new chapter in the
- 324 COVID-19 pandemic. *The Lancet* (2021).
- 325 3 Sanders, R. W. & de Jong, M. D. Pandemic moves and countermoves: vaccines and viral
 326 variants. *The Lancet* (2021).
- 327 4 Choi, E. M. COVID-19 vaccines for low- and middle-income countries. *Trans R Soc*
- 328 *Trop Med Hyg* **115**, 447-456, doi:10.1093/trstmh/trab045 (2021).
- 329 5 Tregoning, J. S., Flight, K. E., Higham, S. L., Wang, Z. & Pierce, B. F. Progress of the
- 330 COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness

and escape. *Nature Reviews Immunology*, 1-11 (2021).

- 332 6 Fischer, W. A., II, M. G., Bhagwanjee, S. & Sevransky, J. Global burden of influenza:
- contributions from resource limited and low-income settings. *Global heart* **9**, 325 (2014).
- Hannah Ritchie *et al.* (Our World in Data, 2020).
- 8 Ramachandran, R., Ross, J. S. & Miller, J. E. Access to COVID-19 Vaccines in High-,
- 336 Middle-, and Low-Income Countries Hosting Clinical Trials. JAMA Network Open 4,
- 337 e2134233-e2134233 (2021).
- 338 9 Knight, K. & Radhakrishnan, A. Omicron Latest Reminder That Global Vaccine Equity
 339 Is Critical, 2021).
- 340 10 World Health Organization. *Tracking SARS-CoV-2 variants*,
- 341 <<u>https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/</u>> (2021).
- 34211Lauring, A. S. & Hodcroft, E. B. Genetic Variants of SARS-CoV-2—What Do They
- 343 Mean? *JAMA* (2021).

- 344 12 Smith-Schoenwalder, C. CDC: Coronavirus Variant First Found in U.K. Now Dominant
- 345 *Strain in U.S.*, <<u>https://www.usnews.com/news/health-news/articles/2021-04-07/cdc-</u>
- 346 <u>coronavirus-variant-first-found-in-uk-now-dominant-strain-in-us</u>> (2021).
- 347 13 Glatter, R. P.1 Variant, Dominant Strain in Brazil, Reported in New York,
- 348 <<u>https://www.forbes.com/sites/robertglatter/2021/03/21/p1-variant-dominant-strain-in-</u>
- 349 <u>brazil-reported-in-new-york/?sh=449db2971883</u>> (2021).
- 350 14 Adam, D. What scientists know about new, fast-spreading coronavirus variants,
- 351 <<u>https://doi.org/10.1038/d41586-021-01390-4</u>>(2021).
- 352 15 Centers for Disease Control and Prevention. Variant Proportions,
- 353 <<u>https://covid.cdc.gov/covid-data-tracker/#variant-proportions</u>> (2021).
- Lopez Bernal, J. *et al.* Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta)
 variant. *N Engl J Med*, 585-594 (2021).
- 356 17 Abu-Raddad, L. J., Chemaitelly, H. & Butt, A. A. Effectiveness of the BNT162b2 Covid-
- 357 19 Vaccine against the B.1.1.7 and B.1.351 Variants. *New England Journal of Medicine*
- **358 385**, 187-189, doi:10.1056/NEJMc2104974 (2021).
- Liu, C. et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and
- 360 convalescent serum. *Cell*, doi:<u>https://doi.org/10.1016/j.cell.2021.06.020</u> (2021).
- Wang, P. *et al.* Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
- 362 *Nature* **593**, 130-135, doi:10.1038/s41586-021-03398-2 (2021).
- 363 20 Grimm, V., Mengel, F. & Schmidt, M. Extensions of the SEIR model for the analysis of
- tailored social distancing and tracing approaches to cope with COVID-19. *Scientific*
- 365 *Reports* **11**, 1-16 (2021).

366	21	Rădulescu, A., Williams, C. & Cavanagh, K. Management strategies in a SEIR-type
367		model of COVID 19 community spread. Scientific reports 10, 1-16 (2020).
368	22	Usherwood, T., LaJoie, Z. & Srivastava, V. A model and predictions for COVID-19
369		considering population behavior and vaccination. Scientific Reports 11, 1-11 (2021).
370	23	Paltiel, A. D., Schwartz, J. L., Zheng, A. & Walensky, R. P. Clinical Outcomes Of A
371		COVID-19 Vaccine: Implementation Over Efficacy: Study examines how definitions and
372		thresholds of vaccine efficacy, coupled with different levels of implementation
373		effectiveness and background epidemic severity, translate into outcomes. Health Affairs,
374		10.1377/hlthaff. 2020.02054 (2021).
375	24	Paltiel, A. D., Zheng, A. & Schwartz, J. L. Speed versus efficacy: quantifying potential
376		tradeoffs in COVID-19 vaccine deployment. Annals of internal medicine (2021).
377	25	Food and Drug Administration. Fact Sheet for Healthcare Providers Administering
378		Vaccine (Vaccine Providers) Emergency Use Authorization (EUA) of the Janssen
379		COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19), 2021).
380	26	Pfizer. Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns
381		Through Up to Six Months Following Second Dose in Updated Topline Analysis of
382		Landmark COVID-19 Vaccine Study, < <u>https://www.pfizer.com/news/press-release/press-</u>
383		release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious> (2021).
384	27	Nanduri, S. et al. Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing
385		SARS-CoV-2 infection among nursing home residents before and during widespread
386		circulation of the SARS-CoV-2 B. 1.617. 2 (Delta) variant—National Healthcare Safety
387		Network, March 1–August 1, 2021. Morbidity and Mortality Weekly Report 70, 1163
388		(2021).

389	28	Centers for Disease Control and Prevention. COVID-19 Vaccinations in the United States,
390		< <u>https://covid.cdc.gov/covid-data-tracker/#vaccinations</u> > (2020).
391	29	You, C. et al. Estimation of the time-varying reproduction number of COVID-19
392		outbreak in China. International Journal of Hygiene and Environmental Health 228,
393		113555 (2020).
394	30	Byrne, A. W. et al. Inferred duration of infectious period of SARS-CoV-2: rapid scoping
395		review and analysis of available evidence for asymptomatic and symptomatic COVID-19
396		cases. BMJ open 10, e039856 (2020).
397	31	Centers for Disease Control and Prevention. COVID-19 Pandemic Planning Scenarios,
398		< <u>https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html</u> > (2020).
399	32	Basu, A. Estimating The Infection Fatality Rate Among Symptomatic COVID-19 Cases
400		In The United States: Study estimates the COVID-19 infection fatality rate at the US
401		county level. Health Affairs 39, 1229-1236 (2020).
402	33	Oran, D. P. & Topol, E. J. Prevalence of asymptomatic SARS-CoV-2 infection: a
403		narrative review. Annals of internal medicine 173, 362-367 (2020).
404	34	Centers for Disease Control and Prevention. COVID Data Tracker,
405		< <u>https://covid.cdc.gov/covid-data-tracker/#datatracker-home</u> > (2020).
406	35	Kung, S. et al. Underestimation of COVID-19 mortality during the pandemic. ERJ open
407		research 7 (2021).
408	36	Wu, S. L. et al. Substantial underestimation of SARS-CoV-2 infection in the United
409		States. Nature communications 11, 1-10 (2020).
410	37	Noh, J. & Danuser, G. Estimation of the fraction of COVID-19 infected people in US
411		states and countries worldwide. PloS one 16, e0246772 (2021).

- 412 38 Bushwick, S. Why COVID Vaccines Are Taking So Long to Reach You,
- <https://www.scientificamerican.com/article/why-covid-vaccines-are-taking-so-long-to-413
- 414 reach-you/> (2021).
- 415 39 Johnson & Johnson. Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA for
- 416 *Emergency Use - First Single-Shot Vaccine in Fight Against Global Pandemic.*
- 417 <https://www.jnj.com/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-
- 418 emergency-usefirst-single-shot-vaccine-in-fight-against-global-pandemic> (2021).
- 419 40 Robishaw, J. D. et al. Genomic surveillance to combat COVID-19: challenges and
- 420 opportunities. The Lancet Microbe (2021).
- Cyranoski, D. Alarming COVID variants show vital role of genomic surveillance. 421 41
- 422 https://www.nature.com/articles/d41586-021-00065-4 (2021).
- 423 42 Anthes, E. Why Didn't the U.S. Detect Omicron Cases Sooner?,
- 424 https://www.nytimes.com/2021/12/02/health/omicron-variant-genetic-
- 425 surveillance.html> (2021).
- 426 43 Tindale, L. C. et al. Evidence for transmission of COVID-19 prior to symptom onset.
- *Elife* **9**, e57149 (2020). 427
- Cevik, M. et al. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, 428 44
- 429 duration of viral shedding, and infectiousness: a systematic review and meta-analysis.
- The Lancet Microbe (2020). 430

- Dyer, O. Covid-19: Many poor countries will see almost no vaccine next year, aid groups 431 45 warn. BMJ: British Medical Journal (Online) 371 (2020).
- 433 Andrew, S. More than 130 countries don't have a single Covid-19 vaccine, while 10 46
- 434 countries have already dispersed 75% of all vaccines, the UN says,

- 435 <<u>https://www.cnn.com/2021/02/18/world/united-nations-130-countries-no-vaccine-</u>
- 436 $\underline{\text{trnd/index.html}} > (2021).$
- 437 47 Acharya, K. P., Ghimire, T. R. & Subramanya, S. H. Access to and equitable distribution
- 438 of COVID-19 vaccine in low-income countries. *npj Vaccines* **6**, 54, doi:10.1038/s41541-
- 439 021-00323-6 (2021).

441 Supplemental Materials

442 Supplemental Table 1: Infection attack rate (%) under different capacity multipliers and mutation

443 times

Capacity		Mut	ation Ti	me = Da	y 10	Mutation Time = Day 15								
multiplier (λ)	H _i H _f	$\mathrm{H}_{\mathrm{i}}\mathrm{M}_{\mathrm{f}}$	H_iL_f	M_iM_f	$M_{i}L_{f}$	$L_i L_f$		H _i H _f	$\mathrm{H}_{i}\mathrm{M}_{f}$	H_iL_f	M_iM_f	$M_i L_f$	L_iL_f	
3.0	60.08	62.41	63.74	63.43	64.79	65.32		59.98	61.86	62.94	63.32	64.44	65.20	
2.8	61.06	63.34	64.64	64.31	65.63	66.13		60.96	62.82	63.88	64.20	65.30	66.02	
2.6	62.08	64.31	65.57	65.23	66.50	66.97		61.99	63.82	64.85	65.12	66.19	66.87	
2.4	63.16	65.33	66.53	66.18	67.41	67.84		63.07	64.86	65.86	66.08	67.11	67.75	
2.2	64.28	66.38	67.53	67.17	68.34	68.75		64.20	65.94	66.90	67.08	68.07	68.66	
2.0	65.47	67.47	68.57	68.20	69.31	69.69		65.39	67.06	67.98	68.12	69.06	69.60	
1.8	66.71	68.61	69.64	69.28	70.32	70.66		66.64	68.23	69.11	69.20	70.09	70.58	
1.6	68.01	69.79	70.75	70.39	71.36	71.66		67.95	69.45	70.27	70.32	71.15	71.59	
1.4	69.38	71.02	71.90	71.55	72.44	72.70		69.32	70.72	71.47	71.49	72.25	72.64	
1.2	70.81	72.30	73.09	72.76	73.55	73.78		70.76	72.04	72.71	72.71	73.39	73.73	
1.0	72.32	73.63	74.31	74.01	74.70	74.90		72.28	73.40	74.00	73.97	74.57	74.85	

444

445																
	Capacity	Mutation Time = Day 20							Mutation Time = Day 30							
	(λ)	H_iH_f	H_iM_f	H_iL_f	$M_i M_f$	M_iL_f	$L_i L_f$		H_iH_f	H_iM_f	H_iL_f	M_iM_f	M_iL_f	L_iL_f		
	3.0	59.89	61.39	62.24	63.22	64.13	65.10		59.75	60.63	61.14	63.06	63.62	64.92		
	2.8	60.87	62.36	63.21	64.11	65.00	65.92		60.74	61.63	62.14	63.95	64.52	65.75		
	2.6	61.91	63.38	64.21	65.03	65.91	66.77		61.78	62.67	63.18	64.88	65.44	66.61		
	2.4	62.99	64.44	65.25	66.00	66.85	67.66		62.86	63.76	64.26	65.86	66.40	67.51		
	2.2	64.13	65.54	66.33	67.00	67.82	68.57		64.01	64.90	65.39	66.87	67.40	68.43		
	2.0	65.32	66.69	67.45	68.04	68.83	69.52		65.21	66.08	66.57	67.92	68.44	69.39		
	1.8	66.57	67.89	68.62	69.13	69.87	70.51		66.47	67.32	67.80	69.01	69.51	70.39		
	1.6	67.89	69.14	69.82	70.26	70.96	71.53		67.79	68.62	69.07	70.15	70.63	71.42		
	1.4	69.27	70.44	71.07	71.44	72.08	72.58		69.18	69.96	70.39	71.34	71.78	72.48		
	1.2	70.72	71.79	72.37	72.66	73.24	73.68		70.63	71.37	71.76	72.57	72.98	73.59		
	1.0	72.24	73.20	73.70	73.93	74.44	74.81		72.16	72.83	73.19	73.85	74.22	74.73		

Capacity		Mut	ation Ti	me = Da	y 35		Mutation Time = Day 40						
(λ)	H _i H _f	$\mathrm{H}_{\mathrm{i}}\mathrm{M}_{\mathrm{f}}$	H_iL_f	M_iM_f	$M_{i}L_{f}$	$L_i L_f$	H _i H _f	$\mathrm{H}_{i}\mathrm{M}_{f}$	H_iL_f	M_iM_f	$M_{i}L_{f}$	L_iL_f	
3.0	59.70	60.36	60.73	63.00	63.43	64.86	59.66	60.14	60.41	62.94	63.27	64.80	
2.8	60.69	61.36	61.74	63.89	64.33	65.69	60.65	61.14	61.42	63.84	64.17	65.63	
2.6	61.73	62.40	62.79	64.83	65.26	66.55	61.69	62.19	62.47	64.78	65.11	66.50	
2.4	62.82	63.50	63.88	65.80	66.23	67.45	62.78	63.29	63.58	65.75	66.08	67.39	
2.2	63.96	64.65	65.03	66.81	67.23	68.37	63.92	64.44	64.73	66.77	67.09	68.33	
2.0	65.16	65.84	66.22	67.87	68.28	69.34	65.12	65.65	65.94	67.82	68.15	69.29	
1.8	66.42	67.10	67.47	68.97	69.36	70.34	66.39	66.91	67.19	68.93	69.24	70.29	
1.6	67.75	68.40	68.76	70.11	70.49	71.37	67.71	68.23	68.51	70.07	70.37	71.33	
1.4	69.14	69.77	70.11	71.30	71.66	72.44	69.11	69.60	69.87	71.26	71.55	72.41	
1.2	70.60	71.19	71.51	72.54	72.87	73.55	70.57	71.04	71.30	72.51	72.77	73.52	
1.0	72.14	72.68	72.97	73.82	74.12	74.70	72.11	72.55	72.78	73.80	74.04	74.67	

447

- 449 Supplemental Table 2: Minimum required capacity multiplier of each vaccine type under
- 450 different mutation times to achieve a lower IAR than vaccine- H_iH_f with the capacity multipliers
- 451 of 1.0 and 1.6

Mutation Time	H_iH_f : Capacity multiplier = 1.0					H_iH_f : Capacity multiplier = 1.6				
	H_iM_f	H_iL_f	M_iM_f	M_iL_f	$L_i L_f$	H_iM_f	H _i L _f	M_iM_f	M_iL_f	$L_i L_f$
5	1.24	1.40	1.28	1.45	1.48	1.97	2.23	2.04	2.33	2.37
10	1.2	1.33	1.28	1.43	1.48	1.91	2.11	2.04	2.27	2.37
15	1.17	1.27	1.28	1.4	1.47	1.85	2.01	2.04	2.23	2.36
20	1.14	1.22	1.27	1.38	1.47	1.81	1.93	2.03	2.19	2.35
25	1.12	1.18	1.27	1.36	1.47	1.77	1.86	2.03	2.16	2.35
30	1.1	1.15	1.27	1.34	1.46	1.73	1.81	2.03	2.13	2.34
35	1.08	1.12	1.27	1.33	1.46	1.7	1.76	2.03	2.11	2.34
40	1.06	1.09	1.27	1.31	1.46	1.68	1.72	2.03	2.09	2.34

452

453